Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 18;22(11):67.
doi: 10.1007/s11883-020-00887-z.

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

Peter E Penson  1   2   3 , Maciej Banach  4   5   6
Affiliations
Review

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

Peter E Penson et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: We aimed to summarize recent guidelines, position papers, and high-quality clinical research relating the use of nutraceuticals in the management of individuals at high risk of atherosclerotic cardiovascular disease.

Recent findings: It is essential that individuals at high risk of cardiovascular disease receive guideline-directed evidence-based therapies to reduce their risk of morbidity and mortality from cardiovascular events. Compared with conventional therapeutics, nutraceuticals have undergone relatively little investigation in randomized controlled trials. Thus, recommendations for nutraceuticals in international guidelines are rare, and nutraceuticals should not be used preferentially in place of statins. Nevertheless, recent position papers from the International Lipid Expert Panel and clinical evidence from studies of triglyceride reduction by polyunsaturated fatty acid administration demonstrate that nutraceuticals do have an important role in optimizing therapy in individuals at high risk of cardiovascular disease. Roles for nutraceuticals include as follows: (1) managing residual risk associated with lipids other than low-density lipoprotein cholesterol (LDL-C); (2) managing non-lipid-mediated residual risk; (3) optimizing LDL-C treatment in statin intolerance; (4) optimizing LCL-C treatment when add-on therapies for statins are not available; (5) as adjuncts to lifestyle for individuals at high lifetime risk of atherosclerotic cardiovascular disease (ASCVD). The strength of evidence for each of these applications is variable. In addition to guideline-directed therapeutics, nutraceuticals may have roles in optimizing preventative therapy and _targeting residual risk in individuals at high risk of ASCVD. Application of Good Manufacturing Practice and randomized controlled trials when producing and evaluating nutraceuticals will expand the armoury of evidence-based agents for the prevention of ASCVD.

Keywords: Efficacy; Lipid disorders; Nutraceuticals; Safety; Therapy.

PubMed Disclaimer

Conflict of interest statement

PEP owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Napp, and Sanofi; MB, speakers bureau: Abbott/Mylan, Abbott Vascular, Actavis, AKCEA, Amgen, Biofarm, KRKA, MSD, Polpharma, Sanofi-Aventis, Servier, and Valeant; consultant to Abbott Vascular, AKCEA, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Lilly, MSD, Polfarmex, Resverlogix, and Sanofi-Aventis; and grants from Sanofi and Valeant.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7(Suppl 1):S21–S31. doi: 10.21037/cdt.2017.03.20.. - DOI - PMC - PubMed
    1. DeFelice SL. The nutraceutical revolution - its impact on food-industry R-and-D. Trends Food Sci Technol. 1995;6(2):59–61. doi: 10.1016/S0924-2244(00)88944-X. - DOI
    1. Mazza G Functional foods: biochemical and processing aspects. CRCs; 1998.
    1. World Health Organization. World Health Statistics 2018: monitoring health for the SDGs 2018.
    1. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation. 1966;34(4):679–697. doi: 10.1161/01.cir.34.4.679. - DOI - PubMed

MeSH terms

Substances

  NODES
admin 2
INTERN 5
twitter 2